Compare Stocks

Date Range: 

 Karyopharm TherapeuticsBELLUS HealthLexicon PharmaceuticalsZIOPHARM OncologyXenon Pharmaceuticals
SymbolNASDAQ:KPTIOTCMKTS:BLUSFNASDAQ:LXRXNASDAQ:ZIOPNASDAQ:XENE
Price Information
Current Price$8.14$3.85$4.46$2.99$18.14
52 Week RangeBuyN/AHoldHoldBuy
MarketRank™
Overall Score1.70.51.61.31.6
Analysis Score3.40.03.23.23.5
Community Score3.02.52.52.42.7
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.81.7
Earnings & Valuation Score0.60.00.60.00.0
Analyst Ratings
Consensus RecommendationBuyN/AHoldHoldBuy
Consensus Price Target$27.75N/A$9.40$5.90$25.25
% Upside from Price Target240.91% upsideN/A110.76% upside97.32% upside39.20% upside
Trade Information
Market Cap$611.00 million$612.60 million$643.82 million$643.46 million$743.07 million
Beta0.931.552.092.281.2
Average Volume2,453,63339,6103,808,4652,516,593180,740
Sales & Book Value
Annual Revenue$40.89 million$30,000.00$322.07 million$150,000.00$6.83 million
Price / Sales14.9420,420.022.004,289.75108.79
CashflowN/AN/A$2.00 per shareN/AN/A
Price / CashN/AN/A2.23N/AN/A
Book Value$0.79 per share$0.25 per share$1.10 per share$0.52 per share$2.99 per share
Price / Book10.3015.404.055.756.07
Profitability
Net Income$-199,590,000.00$-7,010,000.00$130.13 million$-117,800,000.00$-41,600,000.00
EPS($3.22)N/A$1.35($0.34)($1.54)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-221.23%-49,910.34%-320.44%N/A-102.25%
Return on Equity (ROE)-187.66%-48.37%-164.96%-48.49%-21.76%
Return on Assets (ROA)-56.42%-45.25%-31.83%-43.53%-16.08%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.38%N/A0.13%N/AN/A
Current Ratio5.42%13.87%1.54%10.12%9.83%
Quick Ratio5.39%13.87%1.55%10.12%9.83%
Ownership Information
Institutional Ownership Percentage88.56%N/A84.62%48.00%79.90%
Insider Ownership Percentage13.26%24.17%6.40%2.30%8.35%
Miscellaneous
Employees4321078103123
Shares Outstanding75.06 million159.12 million144.35 million215.21 million40.96 million
Next Earnings Date8/3/2021 (Estimated)N/A5/6/2021 (Confirmed)5/6/2021 (Confirmed)5/11/2021 (Confirmed)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Xenon Pharmaceuticals (XENE) to Release Quarterly Earnings on TuesdayXenon Pharmaceuticals (XENE) to Release Quarterly Earnings on Tuesday
americanbankingnews.com - May 5 at 11:13 AM
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Corporate UpdateXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Corporate Update
finance.yahoo.com - May 4 at 8:20 PM
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up to $18.32Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up to $18.32
americanbankingnews.com - May 3 at 12:06 PM
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by BrokeragesXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages
americanbankingnews.com - April 27 at 4:56 AM
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Expected to Announce Quarterly Sales of $3.70 MillionXenon Pharmaceuticals Inc. (NASDAQ:XENE) Expected to Announce Quarterly Sales of $3.70 Million
americanbankingnews.com - April 27 at 1:34 AM
-$0.45 EPS Expected for Xenon Pharmaceuticals Inc. (NASDAQ:XENE) This Quarter-$0.45 EPS Expected for Xenon Pharmaceuticals Inc. (NASDAQ:XENE) This Quarter
americanbankingnews.com - April 25 at 10:12 PM
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 6.4%Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 6.4%
americanbankingnews.com - April 22 at 3:18 PM
Xenon Pharmaceuticals (NASDAQ:XENE)  Shares Down 3.3% Xenon Pharmaceuticals (NASDAQ:XENE) Shares Down 3.3%
americanbankingnews.com - April 21 at 3:44 PM
Xenon Pharmaceuticals (NASDAQ:XENE) Trading Up 6.8%Xenon Pharmaceuticals (NASDAQ:XENE) Trading Up 6.8%
americanbankingnews.com - April 15 at 1:50 PM
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up to $18.12Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up to $18.12
americanbankingnews.com - April 14 at 1:00 PM
How Many Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Do Institutions Own?How Many Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Do Institutions Own?
finance.yahoo.com - April 13 at 6:45 PM
Xenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS DayXenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS Day
finance.yahoo.com - March 29 at 7:15 PM
Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters Option to Purchase Additional SharesXenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
benzinga.com - March 14 at 11:36 PM
Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of ...Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of ...
apnews.com - March 12 at 9:51 PM
Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesXenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - March 12 at 3:40 PM
Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public OfferingXenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering
finance.yahoo.com - March 10 at 1:21 AM
Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at ...Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at ...
apnews.com - March 8 at 6:48 PM
Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)
finance.yahoo.com - March 8 at 6:48 PM
Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate UpdateXenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update
finance.yahoo.com - March 1 at 8:31 PM
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Tops Revenue EstimatesXenon Pharmaceuticals (XENE) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 1 at 8:31 PM
Xenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview ...Xenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview ...
apnews.com - February 22 at 6:25 PM
Xenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview of its XEN1101 Program at ASENT 2021Xenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview of its XEN1101 Program at ASENT 2021
finance.yahoo.com - February 22 at 6:25 PM
If You Had Bought Xenon Pharmaceuticals (NASDAQ:XENE) Shares Three Years Ago Youd Have Earned 316% ReturnsIf You Had Bought Xenon Pharmaceuticals (NASDAQ:XENE) Shares Three Years Ago You'd Have Earned 316% Returns
finance.yahoo.com - February 12 at 5:26 PM
Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021
finance.yahoo.com - January 14 at 10:27 AM
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at AES2020, the Virtual ...Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at AES2020, the Virtual ...
apnews.com - December 8 at 4:01 PM
DateCompanyBrokerageAction
5/4/2021Karyopharm TherapeuticsRobert W. BairdLower Price Target
5/4/2021Karyopharm TherapeuticsRoyal Bank of CanadaLower Price Target
5/3/2021Karyopharm TherapeuticsSVB LeerinkLower Price Target
2/12/2021Karyopharm TherapeuticsBarclaysLower Price Target
11/3/2020Karyopharm TherapeuticsMorgan StanleyLower Price Target
7/14/2020Karyopharm TherapeuticsHC WainwrightReiterated Rating
6/23/2020Karyopharm TherapeuticsJPMorgan Chase & Co.Boost Price Target
6/23/2020Karyopharm TherapeuticsWedbushBoost Price Target
5/6/2020Karyopharm TherapeuticsCanaccord GenuityReiterated Rating
1/15/2021Lexicon PharmaceuticalsG.ResearchDowngrade
1/15/2021Lexicon PharmaceuticalsCitigroupBoost Price Target
1/15/2021Lexicon PharmaceuticalsGabelliDowngrade
1/14/2021Lexicon PharmaceuticalsSmith Barney CitigroupBoost Price Target
12/8/2020Lexicon PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgrade
4/27/2020Lexicon PharmaceuticalsNeedham & Company LLCReiterated Rating
3/18/2021ZIOPHARM OncologyJefferies Financial GroupReiterated Rating
3/12/2021ZIOPHARM OncologyRaymond JamesSet Price Target
6/21/2020ZIOPHARM OncologyLaidlawReiterated Rating
6/21/2020ZIOPHARM OncologyCantor FitzgeraldReiterated Rating
3/5/2021Xenon PharmaceuticalsWilliam BlairReiterated Rating
8/13/2020Xenon PharmaceuticalsBloom BurtonReiterated Rating
9/20/2019Xenon PharmaceuticalsGuggenheimInitiated Coverage
3/29/2019Xenon PharmaceuticalsStifel NicolausReiterated Rating
(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.